A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Study Identifier:

VIS171-103

ClinicalTrials.gov Identifier:

NCT06799520

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

617-498-1070 or [email protected]

Recruiting

Subscribe to Updates

Study Details

Medical Condition

Autoimmune Disease
Autoimmune

Study Drug

Drug: VIS171

Date

Mar 2025 - Dec 2026

Phase 1/2

Phase 2/3

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 18 - 75 Years

Requirements Information

Protocol Summary

The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s). The total duration of the clinical trial for each participant will be up to approximately 9 to 12 months.

Study Locations

Location

Status

Location

Visterra Investigational Site

Chisinau, Republic of Moldova, MD-2001

Status

Recruiting